{"id":767019,"date":"2023-06-29T11:24:15","date_gmt":"2023-06-29T15:24:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/"},"modified":"2023-06-29T11:24:15","modified_gmt":"2023-06-29T15:24:15","slug":"sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/","title":{"rendered":"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+\/HER2- metastatic breast cancer<\/em><br \/>\n          \n        <\/li>\n<li>\n          <em>Second poster shares survey results examining vaginal and sexual health in ER+\/HER2- metastatic breast cancer patients<\/em>\n        <\/li>\n<\/ul>\n<p>COLUMBUS, Ohio, June  29, 2023  (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring <em>ESR1<\/em> mutations, today announced it will present two posters, addressing sexual and urogenital health of metastatic breast cancer patients, at The Menopause Society (formerly North American Menopause Society, or NAMS) 2023 Annual Meeting, to be held Sept. 27-30 at the Downtown Marriott in Philadelphia.<\/p>\n<p>\u201cQuality of life, which includes sexual and overall genitourinary health, is a constant concern for the vast majority of women confronted with metastatic breast cancer,\u201d said Dr. David Portman, founder and chief executive officer of Sermonix. \u201cOur lead investigational drug, lasofoxifene, has demonstrated potential benefit with respect to vaginal and sexual health, and we are excited to continue investigating this vitally important aspect of disease management during our upcoming Phase 3 study. We look forward to engaging with our peers at The Menopause Society 2023 Annual Meeting and sharing our most recent findings.\u201d<\/p>\n<p>Sermonix will share its two posters Thursday, Sept. 28, from 6:15-7:15 p.m. ET. They are:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong><br \/>\n            <em>\u201cVaginal and vulvar symptoms in patients with ESR1-mutated, ER+\/HER2- metastatic breast cancer by baseline characteristics\u201d<\/em><br \/>\n          <\/strong><br \/>\n          <br \/>The objective of this analysis was to evaluate the effects of patient characteristics on baseline vaginal\/vulvar symptoms in the Phase 2 <em>Evaluation of Lasofoxifene in ESR1 Mutations<\/em> (ELAINE-1) study assessing the efficacy and safety of oral lasofoxifene versus intramuscular fulvestrant.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong><br \/>\n            <em>\u201cVaginal and sexual health in patients with ER+\/HER2- metastatic breast cancer (mBC)\u201d<\/em><br \/>\n          <\/strong><br \/>\n          <br \/>This poster analyzes the results of the 50-question, online EQUALS 2 (<em>ESR1<\/em> QUAlity of Life Survey 2) survey, whose objective was to better understand vaginal and sexual health concerns of women with ER+\/HER2- metastatic breast cancer.<\/li>\n<\/ul>\n<p>\u201cThe theme of this year\u2019s meeting is \u2018Midlife Women\u2019s Health in the Era of Precision Medicine,\u2019\u201d said Dr. Lisa Larkin, president-elect of The Menopause Society board of trustees. \u201cSermonix\u2019s efforts in the precision medicine women\u2019s oncology space is significant and its investigation of targeted therapy lasofoxifene\u2019s impact on vaginal and sexual health is much needed in an arena that is currently so underserved. We look forward to Sermonix\u2019s participation in The Menopause Society Annual Meeting and as a member of our 2023 Corporate Liaison Council.\u201d<\/p>\n<p>Sermonix in March initiated ELAINE-3, a registrational Phase 3 study of 400 patients assessing the efficacy of lasofoxifene and abemaciclib. Enrollment will begin soon.<\/p>\n<p>To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jGlivfLA8mUR3bVJYBnw1RaiNFbaZsqzMI8_hkzmHlxgMSJnljPj2C3bh3wZZXLgLBVB_2H7lSXhsqV1HwvN0DoYMNu42JePFEWKyYTZdNCzVpXeWtniDIM4EqdM1SFz1WxgGmpiP3RSzb-RH4i909Rk4nCvHQ-udl1SAlqqqZfKkY1dVH6waf8TPjsIlUOZHuk_eVFNMZxZl8tThnkUgp2ZMyjlHhKvqoD22IaSKR2phSOfXwd_rnRRV8HckcI-R7slee2qOB87R9Q8NNfiJQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/sermonixpharma.com<\/u><\/a>. To learn more about the ELAINE studies, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jGlivfLA8mUR3bVJYBnw1RNxXujR2LS1XiUfygeoN9kTowCfxq1UqtqveBzxqsV9q2YWrMUrup0GcBvmvDmQy5g03HXHUluh99XKjhcxVrSJGVtwFbenqvw-CJ9gfq1z4hTsSkpxHxEFV-GwTjal3bVISSi2HnaCgB8nx-dhE2OqJNH7-RreB0QOXyBR5aXMmzZRhnX8r2FxE-FlNn64_E9nGqDSJZpaY3YPLFGWMF1sN1cA71yWCys_dHiF1xg0xnCD9ykBkfIRzdH-MDBoaA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/elainestudy.com\/<\/u><\/a>.<\/p>\n<p>\n        <strong>About Lasofoxifene<\/strong><br \/>\n        <br \/>Lasofoxifene is an investigational novel endocrine therapy in clinical development which has demonstrated robust target engagement as an <em>ESR1<\/em> antagonist in the breast, particularly in the presence of <em>ESR1<\/em> mutations. Lasofoxifene has demonstrated anti-tumor activity as monotherapy and in combination with a CDK4\/6 inhibitor in Phase 2 studies and has unique tissue selectivity distinguishing it from other current and investigational endocrine therapies, with beneficial effects seen on vagina and bone in previous clinical studies. Lasofoxifene, which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ:LGND), has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene\u2019s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to <em>ESR1<\/em> mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene\u2019s novel activity in <em>ESR1<\/em> mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a novel targeted and tissue selective oral endocrine therapy could, if approved, play a critical role in the precision medicine treatment of advanced ER+ breast cancer.<\/p>\n<p>\n        <strong>About Sermonix<\/strong><br \/>\n        <br \/>Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking two Phase 2 clinical studies of lasofoxifene, its lead investigational drug. The Sermonix management team, led by founder Dr. David Portman, has significant experience in all stages of the drug development, regulatory and commercialization processes. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience at AstraZeneca in the breast cancer drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in nuclear receptor biology. Miriam Portman, M.D., is co-founder and chief operating officer, with expertise in clinical trial conduct and patient recruitment. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D., vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert\u2019s Pharmaceutical Division. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7F8pEXimKr6uEgmA98aSaEKfKADPZACHGP0fMvBibZpf1gSlH3lQIM1uR35CLUA0_x7oo2cXMprUQUp1_QrmBRLgnS-o6xlSQpJ6bLovW3Mqplrz0FIEgeuZRrsO-CwxH8hkq_mb6hOZFIVInj4US4c8aCRT15T28S_jGObUcfA0xxLEc_c8mjD03s3cQyi8I3SVlft04xMSlJ7atD37JN5WS6AykVVGjTdHl8bzu1ZFOPfdESEIf1s6q7ofrdDdxsmPubnK0-MfF9IO7GW1jj-0zY7cifVjiopZRSGTZ23r2l9FbJYR2RF4_IDnFBQH68R0Q9mplbILF9F2IuNWUO1g7KMuO_NgJnMadSM6Zvw5UtlsVH1iL1ykH9uQdWWbT1_J_mZG96g-miSUkCrSTbbDd-9D6JT_RTNGIAXIGj4dfuHmEkmJRDRN1aqa1GIzbe3MfQSqRCvRiIKXrcHJnA==\" rel=\"nofollow noopener\" target=\"_blank\">SermonixPharma.com<\/a>.<\/p>\n<p>\n        <strong>Sermonix Media Contact:<\/strong><br \/>\n        <br \/>Monica Kozlowski, MSPH<br \/>Sermonix Product Manager<br \/>mkozlowski@sermonixpharma.com<br \/>860-692-8548<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWExMWY4OTgtZGNiZi00OGZiLWEwZjEtZTIzZWQxYmU0ZmZjLTUwMDA1MTg2MA==\/tiny\/Sermonix-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+\/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+\/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it will present two posters, addressing sexual and urogenital health of metastatic breast cancer patients, at The Menopause Society (formerly North American Menopause Society, or NAMS) 2023 Annual Meeting, to be held Sept. 27-30 at the Downtown Marriott in Philadelphia. \u201cQuality of life, which includes sexual and overall genitourinary health, is a constant concern for the vast majority of women &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-767019","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+\/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+\/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it will present two posters, addressing sexual and urogenital health of metastatic breast cancer patients, at The Menopause Society (formerly North American Menopause Society, or NAMS) 2023 Annual Meeting, to be held Sept. 27-30 at the Downtown Marriott in Philadelphia. \u201cQuality of life, which includes sexual and overall genitourinary health, is a constant concern for the vast majority of women &hellip; Continue reading &quot;Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-29T15:24:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting\",\"datePublished\":\"2023-06-29T15:24:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/\"},\"wordCount\":852,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/\",\"name\":\"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==\",\"datePublished\":\"2023-06-29T15:24:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting - Market Newsdesk","og_description":"One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+\/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+\/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it will present two posters, addressing sexual and urogenital health of metastatic breast cancer patients, at The Menopause Society (formerly North American Menopause Society, or NAMS) 2023 Annual Meeting, to be held Sept. 27-30 at the Downtown Marriott in Philadelphia. \u201cQuality of life, which includes sexual and overall genitourinary health, is a constant concern for the vast majority of women &hellip; Continue reading \"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-29T15:24:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting","datePublished":"2023-06-29T15:24:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/"},"wordCount":852,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/","name":"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==","datePublished":"2023-06-29T15:24:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NjY4MiM1NjcwNDA1IzUwMDA1MTg2MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=767019"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/767019\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=767019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=767019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=767019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}